Results 171 to 180 of about 175,170 (271)

Targeting Replication Fork Processing Synergizes with PARP Inhibition to Potentiate Lethality in Homologous Recombination Proficient Ovarian Cancers

open access: yesAdvanced Science, EarlyView.
This study demonstrates that the resveratrol analogue, trans‐4,4′‐dihydroxystilbene (DHS), exhibits synergistic anti‐tumor activity with the PARP inhibitor talazoparib, inducing significant ovarian cancer cell death. The synergistic effect of this combination arises from the concurrent downregulation of homologous recombination factors and the ...
Ganesh Pai Bellare   +7 more
wiley   +1 more source

Genetic and Epigenetic Modification of MLH1 Accounts for a Major Share of Microsatellite-Unstable Colorectal Cancers [PDF]

open access: green, 2000
Shannon A. Kuismanen   +4 more
openalex   +1 more source

Delivery of A Chemically Modified Noncoding RNA Domain Improves Dystrophic Myotube Function

open access: yesAdvanced Science, EarlyView.
CYTOR is a pro‐myogenic ncRNA in skeletal muscle. Here, chemical probing of CYTOR, coupled with functional cellular assays identifies exon 2 as an independent myogenic RNA domain. Chemical engineering of CYTOR exon 2 RNA improves pharmacologic properties, including RNA stability and cell‐autonomous immunogenicity.
Zeinabou Niasse‐Sy   +6 more
wiley   +1 more source

CK2B Induces CD8+ T‐Cell Exhaustion through HDAC8‐Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti‐PD‐1 Therapy in Non‐Small‐Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
αPD‐1 therapy has left an indelible mark in the field of NSCLC treatment; however, its efficacy is limited in clinical practice owing to the effector T‐cell exhaustion. These findings underscore CK2B as a promising target for overcoming the exhaustion of effector CD8+ T cells, thereby enhancing the efficacy of αPD‐1 and adoptive cell therapies in NSCLC.
Shaochuan Liu   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy